SOUTH SAN FRANCISCO, June 3, 2011 /PRNewswire/ — Rigel
Pharmaceuticals, Inc. (Nasdaq:
RIGL) today announced that James M. Gower, the company’s
chairman and chief executive officer, is scheduled to present a
company overview at the Jefferies 2011 Global Healthcare Conference
in New York City on Wednesday, June 8th at 2:30 pm ET.

The presentation will be webcast live and can be accessed at www.rigel.com.  Please
connect to Rigel’s website several minutes prior to the start of
the live webcast to ensure adequate time for any software download
that may be necessary.

About Rigel (www.rigel.com)

Rigel is a clinical-stage drug development company that
discovers and develops novel, small-molecule drugs for the
treatment of inflammatory and autoimmune diseases, as well as
muscle disorders. Rigel’s pioneering research focuses on
intracellular signaling pathways and related targets that are
critical to disease mechanisms. Rigel’s productivity has resulted
in strategic collaborations with large pharmaceutical partners to
develop and market its product candidates. Current product
development programs include fostamatinib, an oral syk inhibitor
that has started its phase 3 clinical trial program for rheumatoid
arthritis, and R343, an inhaled syk inhibitor that has completed
Phase 1 clinical trials for asthma.

Contact: Ryan Maynard

Phone: 650.624.1284

Email:
invrel@rigel.com

‘/>”/>

SOURCE